Why the study?
Few studies have compared the efficacy of nifekalant and amiodarone for resuscitation after cardiopulmonary arrest due to shock-resistant ventricular fibrillation in Japan.
Key points are not available for this paper at this time.
Comparison
Nifekalant versus amiodarone for resuscitation after shock-resistant ventricular fibrillation
Design
Other
Nifekalant (NIF) is a pure potassium channel blocker developed in Japan and it has been used widely for treating fatal ventricular tachyarrhythmia since 1999. Because intravenous amiodarone (AMD) was approved in 2007 in Japan, there have been few studies about the comparison of the efficacy of NIF and AMD for resuscitation after cardiopulmonary arrest patients due to shock-resistant ventricular fibrillation.
No takes yet. Share an insight, caveat, or question.
Harayama et al. (2011) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: